stockrowSol-Gel Technologies Ltd.
SLGLSol-Gel Technologies Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $19.4 million, up 68.0% from fiscal 2024.
- Revenue
- −96.6%
- EPS
- −127.1%
- Free cash flow
- −8.76%
Quarter to June 2026, against a year earlier
Follow SLGL
Alert me
Sol-Gel Technologies Ltd. (SLGL) EV/Sales
As of 6 November 2026, Sol-Gel Technologies Ltd. (SLGL) trades at a EV/Sales of 121×. Over the past ten years it has ranged from 0.0× (December 2018) to 1,022× (February 2019); the current reading is higher than 93% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.2× | 40.31% |
| FY2024 | 5.8× | (87.12%) |
| FY2023 | 45.3× | 14.51% |
| FY2022 | 39.6× | 477.52% |
| FY2021 | 6.8× | (76.67%) |
| FY2020 | 29.4× | 92.18% |
| FY2019 | 15.3× | (98.22%) |
| FY2018 | 860× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 145× | 1,026.96% |
| Mar 2026 | 12.8× | 56.94% |
| Dec 2025 | 8.2× | 23.55% |
| Sep 2025 | 6.6× | 157.14% |
| 30 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| PLX Protalix BioTherapeutics, Inc. compare | 2.3× |
| RNAC Cartesian Therapeutics, Inc. compare | 77.4× |
| SLGL Sol-Gel Technologies Ltd. | 121× |
| PALI Palisade Bio, Inc. compare | 151× |
| IKT Inhibikase Therapeutics, Inc. compare | 395× |
| IFRX InflaRx N.V. compare | 1,845× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)